Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 21, 2026, titled "Orbicular s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic® (Semaglutide Injection), supported by OneSource as CDMO partner".
Onesource Specialty Pharma Limited Press Release Apr 21 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
OneSource Specialty Pharma Limited has issued a press release regarding a significant development in collaboration with Orbicular Pharmaceutical Technologies. The release announces that Orbicular has secured tentative U.S. FDA approval for a generic version of Ozempic, with OneSource acting as the contract development and manufacturing organization partner. This achievement underscores the integrated development model between Orbicular and OneSource, highlighting their capabilities in manufacturing and regulatory compliance. The press release emphasizes OneSource's commitment to strengthening its position as a global CDMO partner for complex pharmaceutical products.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
OneSource Specialty Pharma Limited on 6ix
Earlier from OneSource Specialty Pharma
- Press Release Feb 11 2026
- Press Release Nov 11 2025
- Press Release Aug 04 2025
- Press Release Jun 11 2025
- Press Release Jun 10 2025
Later from OneSource Specialty Pharma
- Press Release Apr 29 2026
- Press Release May 04 2026
- Press Release May 13 2026
- Onesource Specialty Pharma Limited Press Release Jul 24 2026
- Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY".
Follow OneSource Specialty Pharma into a list and get an email when it puts out news.
Follow OneSource Specialty Pharma